Lidokain/Adrenalin Aguettant (Epinephrine, Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, preventing the initiation and propagation of action potentials. This interruption of nerve signaling results in loss of sensation in the targeted area, producing rapid and effective local anesthesia.

The specific dose and concentration are determined by the prescribing clinician based on the type of procedure, patient weight, and clinical guidelines. Healthcare professionals calculate the appropriate volume to achieve effective anesthesia while staying within safe maximum dose limits.

Safety data for use in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lidokain/Adrenalin Aguettant combines a fast‑acting amide anesthetic (lidocaine) with a vasoconstrictor (epinephrine), offering longer duration and reduced systemic absorption compared with lidocaine alone. Compared with bupivacaine, it has a quicker onset but a shorter duration, making it suitable for shorter procedures.

The solution should be stored at room temperature, below 25 °C, in its original sealed container. Protect it from direct sunlight, moisture, and freezing. Do not use if the solution appears discolored or contains particles.

The product is administered by a qualified healthcare professional via injection. Routes include infiltration into tissue, epidural space, or intravenous regional (Bier) block. Proper aseptic technique and dosage calculation are essential for safe administration.

Serious risks include severe allergic reactions (anaphylaxis), cardiac arrhythmias such as ventricular tachycardia, central nervous system toxicity leading to seizures, and methemoglobinemia. Immediate medical attention is required if any of these events occur.

Patients with known hypersensitivity to lidocaine, epinephrine, or any component of the formulation should avoid this product. It is also contraindicated in individuals with uncontrolled severe hypertension, certain cardiac conduction disorders, or those taking non‑selective MAO inhibitors.